Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects

Trial Profile

Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs LY 3023703 (Primary)
  • Indications Acute pain; Dental pain
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Jan 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 21 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 29 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top